TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03658174

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate-rich beetroot juice
Description: 70mls of concentrated beetroot juice containing approximately 5-6 mmol of inorganic nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-free beetroot juice
Description: 70mls of concentrated beetroot juice that has been nitrate-depleted
Study: NCT04171999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Rx-Hunger (CRx-H)
Description: The CRx-H Intervention provides dosages of health content that offer assistance for food insecurity and other health-related social needs. A caregiver randomized to the intervention will receive a hard-copy print-out of their tailored list of resources to address food insecurity. A member of our research team will deliver this list and provide a brief educational component which includes: a brief, structured script about the common problem of food insecurity in households with children and co-occuring HRSNs, review of the resource list which includes nearby, vetted resources to address these needs and coaching on how to activate resources on the list. Prior to discharge, the caregiver will receive a duplicate copy of the list of resources. After discharge, the caregiver will receive text messages at a frequency based on the Critical Time Intervention (CTI) Model, from baseline to 3 months post discharge, in order to receive ongoing support by a research team member.
Study: NCT00410722

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole wheat and bran muffin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed tree nuts

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed tree nuts
Study: NCT03776630

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Two blood samples (2 tubes of 4 ml for each blood sample) will be collected per patient during the study period for EC and OC. One blood sample will be collected for control population. The first sample will be collected prior to any treatment for EC, OC, and control population.~For EC, the second collection will be done one month post-surgery. For OC, the second collection will be done 6 to 9 months after the initial diagnosis, in most cases at the completion of adjuvant chemotherapy. For control population, there will be no second sample.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Two blood samples (2 tubes of 4 ml for each blood sample) will be collected per patient during the study period for EC and OC. One blood sample will be collected for control population. The first sample will be collected prior to any treatment for EC, OC, and control population.~For EC, the second collection will be done one month post-surgery. For OC, the second collection will be done 6 to 9 months after the initial diagnosis, in most cases at the completion of adjuvant chemotherapy. For control population, there will be no second sample.
Study: NCT01869322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sling and Swathe
Description: Sling and Swathe immobilization of humeral shaft fracture.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coaptation Splint
Description: Coaptation splint immobilization of humeral shaft fractures.
Study: NCT01623310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Using Optinose Exhalation Delivery System
Study: NCT04417790

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound and EVLW measurement by transpulmonary thermodilution.
Description: Lung ultrasonography by 8 Quadrant protocol of Volpicelli et al. Transpulmonary thermodilution for extravascular lung water measurement
Study: NCT02099461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Single sucutaneous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Single sucutaneous dose
Study: NCT03776630

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Two blood samples (2 tubes of 4 ml for each blood sample) will be collected per patient during the study period for EC and OC. One blood sample will be collected for control population. The first sample will be collected prior to any treatment for EC, OC, and control population.~For EC, the second collection will be done one month post-surgery. For OC, the second collection will be done 6 to 9 months after the initial diagnosis, in most cases at the completion of adjuvant chemotherapy. For control population, there will be no second sample.
Study: NCT01503515

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: Given IV or PO
Study: NCT02762500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYC-30937-EC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01350102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacitracin
Description: Participants will be treated with Bacitracin to their wound until 100% wound healing, which may take up to 6 months to achieve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacitracin
Description: Participants will be treated with Bacitracin to their wound until 100% wound healing, which may take up to 6 months to achieve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AmeriGel®
Description: Participants will be treated with AmeriGel® to their wound until 100% wound healing, which may take up to 6 months to achieve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AmeriGel®
Description: Participants will be treated with AmeriGel® to their wound until 100% wound healing, which may take up to 6 months to achieve.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Participants will be treated with Vitamin C supplements 1000 mg daily until 100% wound healing, which may take up to 6 months to achieve

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Participants will be treated with Vitamin C supplements 1000 mg daily until 100% wound healing, which may take up to 6 months to achieve
Study: NCT01985945

Intervention type: OTHER
Group type: OTHER
Intervention: Yoga
Study: NCT01275872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Imagery and Progressive Muscle Relaxation
Description: 4 supervised sessions per patient for 4 weeks additional to daily unsupervised sessions
Study: NCT00003934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study: NCT02099461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous core needle breast biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous core needle breast biopsy
Study: NCT00003934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given IV
Study: NCT02099461

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous core needle breast biopsy
Study: NCT00956228

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radioimmuniguided intenstiy modulated radiotherapy
Description: All patients recieved 75.6 Gy in 42 fractions to the prostate and the region of the prostate which enhanced on prostascint scan was simaltaneously boosted to a total dose of 82 Gy
Study: NCT00003934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Given IV
Study: NCT02211508

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RINCE
Description: The NeuroPoint device is used to deliver repeat applications of RINCE therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RINCE
Description: The NeuroPoint device is used to deliver repeat applications of RINCE therapy
Study: NCT04945356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upper limb training
Description: The 6-week exercise program will consist of evidence-based exercises covering the breadth and depth of rehabilitation interventions. The therapist will choose the appropriate exercises for each participant's level of function from more than 15,000 exercises implemented within the Physiotec app and developed by rehabilitation experts. Personalized upper limb exercises will be based on the therapist initial assessment of participants, using the TERA+ telerehabilitation platform, and their goals. After each training session, participants will have to rate their perceived level of effort on a Borg scale (/10). The Borg scores will be monitored by the therapist as a precautionary measure to ensure safety and appropriateness of intensity of exercises. Participants will be instructed to train at a target score of around 7/10 (somewhat hard) on the Borg scale.
Study: NCT02721628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epi-keratoplasty
Description: Femtosecond laser assisted Epi-keratoplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen Cross-Linking
Description: Collagen Cross-Linking: Standard procedure, which is descriptor bellows: Corneal epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond laser
Description: Use in the epic-keratoplasty surgery
Study: NCT00717925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin (CMC-544)
Description: Intravenous (IV) infusion, 1.3 - 1.8 mg/m2, every 28 days, 4 cycles
Study: NCT00527371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GreenLight HPS (TM)laser system [Photoselective Vaporization of the prostate (PVP)]
Description: Photoselective vaporization of the prostate will be performed using the GreenLight HPS (TM)laser system (American Medical Systems), which is a high-power (120W) potassium titanyl phosphate (KTP) laser which was licensed by Health Canada in April 2007.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral resection of the prostate
Description: Transurethral resection of the prostate will be performed with a continuous flow resectoscope and unipolar cautery using a standard technique.
Study: NCT02061215

Intervention type: OTHER
Intervention: CMV viral load

Intervention type: OTHER
Intervention: CMV viral load
Study: NCT01578278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine besilate formulation
Description: Nasal Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: Nasal Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine besilate-fluticasone propionate
Description: Nasal Spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Nasal Spray
Study: NCT04835662

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Complementary feeding promotion
Description: The intervention engaged fathers through community meetings, religious services, and mobile phone text and voice messages. Mothers received home visits from community health extension workers (CHEWs), which fathers also could attend. Social behavior change communication materials included TV and radio messages, sermon guides, counseling cards, pamphlets, posters, and feeding bowls.
Study: NCT03195621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent implantation
Description: Stent placement after risk factors assessment plus FFR or ultrasound or OCT detection for critical lesions.
Study: NCT00423332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: 45 mg oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cediranib Placebo
Description: oral tablet
Study: NCT01737710

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Intradermal Vaccine
Description: A 0.1mL single-dose, in a latex-free, pre-filled microinjection system with an ultra-fine micro-needle. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® Intradermal is approved for use in persons 18 through 64 years of age and will be purchased from Sanofi Pasteur, Inc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Intradermal Vaccine
Description: A 0.1mL single-dose, in a latex-free, pre-filled microinjection system with an ultra-fine micro-needle. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® Intradermal is approved for use in persons 18 through 64 years of age and will be purchased from Sanofi Pasteur, Inc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Intradermal Vaccine
Description: A 0.1mL single-dose, in a latex-free, pre-filled microinjection system with an ultra-fine micro-needle. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® Intradermal is approved for use in persons 18 through 64 years of age and will be purchased from Sanofi Pasteur, Inc.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® (Intramuscular) vaccine
Description: A 0.5 mL single-dose delivered via syringe using single-dose vials. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® for intramuscular injection is approved for persons 6 months and older and will be purchased from Sanofi Pasteur, Inc.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® (Intramuscular) vaccine
Description: A 0.5 mL single-dose delivered via syringe using single-dose vials. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® for intramuscular injection is approved for persons 6 months and older and will be purchased from Sanofi Pasteur, Inc.
Study: NCT03318978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-benzo[a]pyrene
Description: Oral micro-dose range (25, 50, 100 and 250 ng)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-benzo[a]pyrene
Description: Oral micro-dose range (25, 50, 100 and 250 ng)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-benzo[a]pyrene
Description: Oral micro-dose range (25, 50, 100 and 250 ng)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-benzo[a]pyrene
Description: Oral micro-dose range (25, 50, 100 and 250 ng)
Study: NCT02185118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxygen
Description: 1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~2. Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~2. Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: 1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~2. Treatment of 100% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients.
Study: NCT03789760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SaiLuoTong capsule
Description: 500 subjects are randomly divided into two groups by 3:1. 375 subjects in the active group take two pills(120mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 500 subjects are randomly divided into two groups by 3:1. 125 subjects in the control group take two pills(120mg) of placebo each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
Study: NCT02504242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inject BMP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Locally Harvested Bone
Study: NCT03786328

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Psychiatric Treatment
Description: Standard psychiatric treatment is offered individuals identified with a clinical mental disorder. Treatment will follow golden standard treatment in the psychiatric clinic, meaning a combination of therapy and psychopharmacological treatment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Preventive Psychological Treatment
Description: Preventive Psychological Treatment is offered individuals identified with a sub-clinical mental condition. Treatment consists of 8 sessions of cognitive-behavioural therapy.
Study: NCT03383289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: R-REM training
Description: three training modules for front-line long-term care staff to aid in recognition, management and reporting of R-REM
Study: NCT01672801

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimodipine
Description: oral administration
Study: NCT04752709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELITONE UUI
Description: External electrical stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELITONE UUI
Description: External electrical stimulation
Study: NCT00746889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone acetonide
Description: single intraarticular injection of 40 mg of triamcinolone acetonide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Single intraarticular injection of 1 ml of 0.9% saline
Study: NCT02890576

Intervention type: OTHER
Intervention: telemedicine
Description: Monitoring of patients with cochlear implant with sessions of telemedicine
Study: NCT03058562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-1431
Description: ABX-1431, capsules, 40 mg in the fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-1431
Description: ABX-1431, capsules, 40 mg in the fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-1431
Description: ABX-1431, capsules, 20 mg with a high fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-1431
Description: ABX-1431, capsules, 20 mg with a high fat meal
Study: NCT03569930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flavonoid-based supplements
Description: Ingredients: soybean oil (glycine max), edible gelatin, rutin, borage seed oil (borago officinalis), pineapple dry extract (ananas sativus), glycerol, thickeners (mono and diglycerides of fatty acids), emulsifier (soy lecithin).
Study: NCT01556685

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical and neurological evaluation
Description: The day of the usual IFN beta 1a IM injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical and neurological evaluation
Description: The day of the usual IFN beta 1a IM injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sample
Description: For evaluation of interferon-related Nab
Study: NCT03569930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centella Complex
Description: The components are: Centella Asiatica, Beta-glucan, Arnica, Aloe Vera, Menthol, Devil's claw, perform actions useful to alleviate the painful symptomatology, restore the tone of the venous wall, assist the treatment of microcirculatory damage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard of care
Description: diet rich in water and vegetable fibers, hygienic and anal dilator
Study: NCT01556685

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sample
Description: For evaluation of interferon-related Nab

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sample
Description: genetic evaluation - predisposition to Nab generation

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sample
Description: genetic evaluation - predisposition to Nab generation